MDGL

Madrigal Pharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →

NO
87.8% ABOVE
↓ Approaching Was 93.9% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $254.30
14-Week RSI 58

Madrigal Pharmaceuticals, Inc. (MDGL) closed at $477.60 as of 2026-02-02, trading 87.8% above its 200-week moving average of $254.30. The stock is currently moving closer to the line, down from 93.9% last week. The 14-week RSI sits at 58, indicating neutral momentum.

Over the past 943 weeks of data, MDGL has crossed below its 200-week moving average 15 times. On average, these episodes lasted 34 weeks. The average one-year return after crossing below was -4.7%, suggesting these dips have not historically been reliable buying opportunities for this stock.

With a market cap of $10.8 billion, MDGL is a large-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -41.2%. The stock trades at 17.3x book value.

Share count has increased 28.7% over three years, indicating dilution.

Over the past 18.2 years, a hypothetical investment of $100 in MDGL would have grown to $173, compared to $702 for the S&P 500. MDGL has returned 3.1% annualized vs 11.3% for the index, underperforming the broader market over this period.

In the past 12 months, corporate insiders have made 2 open-market purchases totaling $61,921,024.

Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Growth of $100: MDGL vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After MDGL Crosses Below the Line?

Across 15 historical episodes, buying MDGL when it crossed below its 200-week moving average produced an average return of +13.8% after 12 months (median +6.0%), compared to +9.7% for the S&P 500 over the same periods. 53% of those episodes were profitable after one year. After 24 months, the average return was +20.7% vs +26.9% for the index.

Each line shows $100 invested at the moment MDGL crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Insider Buying Activity

2 conviction buys in the past 12 months (purchases over $500K with meaningful position increases).

DateInsiderTitleValueSharesPosition +%
2025-08-20BAKER BROS ADVISORS, L.P.Unknown$36,941,19797,065+4.7%
2025-08-18BAKER BROS ADVISORS, L.P.Unknown$24,979,82768,618+3.3%

Historical Touches

MDGL has crossed below its 200-week MA 15 times with an average 1-year return of +-4.7% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Jan 2008Feb 2008317.9%+6.3%+99.5%
Mar 2008Aug 20082325.0%-66.4%+92.5%
Sep 2008Jan 20091838.6%-61.1%+75.6%
Feb 2009Dec 20109581.9%-40.7%+89.5%
Jan 2011Apr 20111314.5%-2.8%+176.8%
Jun 2011Jan 20123237.8%+14.6%+176.8%
Feb 2012May 20121317.8%+96.4%+206.6%
Jun 2013Jul 2013824.6%-8.6%+199.9%
Oct 2013Dec 2013927.3%-30.7%+219.6%
Jan 2014Feb 201423.9%-55.4%+155.5%
Mar 2014Dec 201719696.0%-50.7%+166.0%
Jan 2020Feb 202029.0%+51.9%+520.4%
Feb 2020May 20201031.6%+40.6%+454.3%
May 2021Dec 20228253.0%-38.8%+325.3%
Oct 2023Oct 202313.7%+75.0%+296.7%
Average34+-4.7%

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of Friday close, 2026-02-02